Update: The FDA Unanimously Recommends Approval of the First CAR-T Therapy
Update (08/08/2017): The FDA has cleared Kite Pharma, Novartis' main competitor to launch the first…
Update (08/08/2017): The FDA has cleared Kite Pharma, Novartis' main competitor to launch the first…
Kite is charging ahead in Europe with a clinical trial and marketing authorization application as…
Celyad has started the SHRINK trial, which will evaluate the synergistic effects of the company's…
Editor's Note: Novartis did note a death from cerebral hemorrhage in its hearing with the…
Faced with the oft-quoted figure that 90% of clinical trials end in failure, how can…
Transgene will help Servier develop new methods based on viral vectors to improve the precision…
Update (28/06/2017): Cellectis has announced the first administration of UCART123 in its Phase I trial…
Novartis has announced an update on the performance of CTL019, a CAR-T therapy against leukemia…
Cell Medica just acquired Catapult Therapy TCR, set up by UK's CGT Catapult, gaining the…
Celyad has announced no toxicity and stable disease in colorectal cancer patients after just 3…
TxCell has partnered with Inserm and the Nantes University to develop a new class of…
Belgian Celyad is giving Novartis access to its IP for the production of allogeneic CAR-T…